SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | MicrobiomeTrials← Back to trialsNCT07635173
SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2022-09-19Est. Completion: 2024-04-22
Enrollment target: 35 participants Locations- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Glioma
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 …
Orange, United StatesEst. completion Aug 9, 2027
Glioblastoma Multiforme of BrainGliomaGlioblastoma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose o…
Tampa, United StatesEst. completion Jun 2027
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/…
Birmingham, United StatesEst. completion Jun 2028